Podcasts about emicizumab

In this week's episode we'll discuss molecular mimicry in aplastic anemia, novel experiments show that antigens associated with viral infections can mimic epitopes presented on hematopoietic progenitor cells. Then, we'll learn about prophylaxis with subcutaneous emicizumab in infants with hemophilia. Finally we'll see how hydroxyurea is associated with a significant reduction in infections among children with sickle cell anemia in Uganda.Articles featured this week:Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecularmimicryEmicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-labeltrialHydroxyurea reduces infections in children with sickle cell anemia in Uganda

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Tom Childs will help us to understand the goal and clinical benefits of the Factor parallelism method.   Link to previous podcasts: S1E11 – How to be more productive (part 1): implementation of a rules engine  S2E8 - World Hemophilia Day  S2E4 - How to determine factor levels in hemophilia?  Literature sources: Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006: 432–7 (https://ashpublications.org/hematology/article/2006/1/432/19703/Acquired-Factor-VIII-Inhibitors-Pathophysiology). Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl 6): 20–2. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–63 Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41 (6 Suppl 4): S360–8. Collins PW, Chalmers E, Hart D et al.; United Kingdom Haemophilia Centre Doctors' Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162 (6): 758–73 (https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12463). Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017; 8: 25. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (1): 59–72 Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (9): 809–18. Florin L, Desloovere M, Devreese KML. Validation of an automated algorithm for interpretation of lupus anticoagulant testing on the Stago STA R Max (Poster). International Society on Thrombosis and Haemostasis, 2017.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

A relatively new treatment in patients with Haemophilia A, Emicizumab helps to improve management in these patients and significantly reduce their time in hospital. Janine Furmedge and Dr Chris Barnes of the RCH Clinical Haematology team join us to discuss Haemophilia A and the role of this new drug. 

COR2ED Medical Education: In this podcast, two haematology experts discuss their views on the use of immune tolerance induction (ITI) in haemophilia. Prof. Jan Astermark, professor of Clinical Coagulation Medicine from Sweden, and Dr. Katharina Holstein, Haematologist from Germany, talk about whether ITI is still the first choice in patients with haemophilia A with inhibitors. A recent survey on the use of ITI in Europe, conducted by the speakers and other members of the European Collaborative Haemophilia Network, forms the basis of the discussion. In March 2022 the results of the survey were published in the journal Haemophilia. In this podcast episode the two experts discuss the results of the survey and the implications for management of haemophilia A.

In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include: Which patients should have pharmacokinetic-guided therapy?Toxicities with PEGylated extended half-life productsFactor VIII and bone healthFactor VIII peaks, thrombotic risk, and cardiovascular diseaseChoosing between extended half-life products and emicizumab for active patientsRole of fitusiran in the treatment paradigm if approvedPresenters:Miguel A. Escobar, MDProfessor of Medicine and PediatricsDepartment of HematologyUniversity of Texas Health Science CenterMcGovern Medical SchoolDirectorGulf States Hemophilia and Thrombophilia CenterHouston, TexasMark Reding, MDProfessor of MedicineDivision of Hematology, Oncology, and TransplantationDirectorCenter for Bleeding and Clotting DisordersUniversity of MinnesotaMinneapolis, MinnesotaGuy A. Young, MDProfessor of PediatricsDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesUniversity of Southern California Keck School of MedicineLos Angeles, CaliforniaLink to full program, including downloadable slidesets, expert commentary, and on-demand webcast:https://bit.ly/3zZwP6G

In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient's mother on various available treatment options and strategies for optimizing hemophilia A prophylaxis and adherence. Topics include:Overcoming challenges to adherenceChoice of standard vs extended half-life factor VIII vs emicizumabSafety and efficacy data with emicizumabPresenter:Guy A. Young, MDProfessor of PediatricsDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesUniversity of Southern California Keck School of MedicineLos Angeles, CaliforniaLink to full program:https://bit.ly/3FxrVk2

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:Maintaining long-term musculoskeletal healthIdentifying patients most likely to benefit from pharmacokinetics-guided prophylaxisManaging combination therapies in older patients with comorbiditiesYoungest age at which patients can be considered for emicizumabDevelopment of resistance to emicizumabSwitching recombinant factor therapiesUsing bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitorsPotential clinical role of extending FVIII half-life with BIVV001Considerations when dosing emicizumab monthlyPresenters:Michael Callaghan, MDAssociate ProfessorDepartment of HematologyWayne State UniversityHematologistDivision of Hematology/OncologyChildren’s Hospital of MichiganDetroit, MichiganMiguel A. Escobar, MDProfessor of Medicine and PediatricsDepartment of HematologyUniversity of Texas Health Science CenterMcGovern Medical SchoolDirectorGulf States Hemophilia and Thrombophilia CenterHouston, TexasRebecca Kruse-Jarres, MD, MPHProfessorDepartment of MedicineUniversity of WashingtonExecutive/Medical DirectorWashington Institute for CoagulationSeattle, WashingtonContent supported by educational grants from Genentech, a member of the Roche Group; Sanofi Genzyme Corporation; and Takeda Pharmaceutical Company Ltd.Link to full program, including downloadable slidesets, expert commentaries, and on-demand Webcast: http://bit.ly/2MW5uhi

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese. In questa puntata parliamo di:Incyte, Amgen, Bandi di ricerca, Gestione studi clinici, Emofilia, Colchicina.Aziende: Incyte, Amgen.Persone: Soren Giese (Amgen Italia), Andrea Buzzi (Fondazione Paracelso).Nuove terapie: Emicizumab, Colchicina.Patologie: Emofilia A, COVID-19.Lavoro: CRA II, Senior CRA home-based.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese. In questa puntata parliamo di:Incyte, Amgen, Bandi di ricerca, Gestione studi clinici, Emofilia, Colchicina.Aziende: Incyte, Amgen.Persone: Soren Giese (Amgen Italia), Andrea Buzzi (Fondazione Paracelso).Nuove terapie: Emicizumab, Colchicina.Patologie: Emofilia A, COVID-19.Lavoro: CRA II, Senior CRA home-based.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

In this episode, Dr. Steven Pipe, a pediatric hematologist out of the University of Michigan who is also the chair of the National Hemophilia Foundation’s Medical and Scientific Advisory Council (MASAC) discusses the major takeaways from the International Society of Thrombosis and Hemostasis’ (ISTH) 2017 Congress, which took place this July in Berlin, Germany. Dr. Pipe shares the latest updates on non-factor replacement therapies, gene therapy, and more on Episode 5 of BloodStream Media’s Ask The Expert podcast series! Disclaimer: The content contained within Ask The Expert is for informational purposes only. Please consult your healthcare provider before making any decisions about treatment. Have a bleeding disorders-related question you’d like to submit to Ask The Expert? Excellent! You can email it to mailbag@bloodstreammedia.com (Subject: Ask The Expert Question), post it on the wall of our Facebook Page, Facebook.com/BloodStreamMedia or tweet it to us @BloodStreamInfo or @pjlynch (host)   ISTH Congress 2017 Headlines: BioMarin and Spark: http://www.biopharmadive.com/news/hemophilia-ISTH-spark-alnylam-gene-therapy-biomarin/446849/ Idelvion: https://hemophilianewstoday.com/2017/07/14/hemophilia-b-pediatric-adult-patients-benefit-from-idelvion-studies-show/ Emicizumab: https://www.dddmag.com/article/2017/07/positive-results-emicizumab-phase-iii-studies-hemophilia-inhibitors Nuwiq: http://www.businesswire.com/news/home/20170709005080/en/ISTH-2017-Berlin-Octapharma-presents-exciting-Nuwiq%C2%AE Q&A with R&D chief of Bioverativ: https://www.dddmag.com/article/2017/07/bioverativ-r-d-chief-breaks-down-data-blood-disorder-drug-pipeline Steven Pipe presents small molecule therapies: http://isthcongressdaily.org/novel-therapies-hemophilia-small-molecules-treatment-hemophilia/  

On this episode, Dr. Steven Pipe- pediatric hematologist and Chair of the National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council- provides an update on new and developing treatment products immediately following his attending the International Society on Thrombosis and Hemostasis (ISTH) Congress. Natalie leads a discussion on a recent CDC study that indicates opioid prescriptions are on the decline, Patrick initiates a game based on a new bleeding disorders online platform, and a community member shares her take on platelet disorders. All this and more on Episode 14 of The BloodStream Podcast!  Opioid Prescriptions Fall After 2010 Peak, C.D.C Report Finds https://www.nytimes.com/2017/07/06/health/opioid-painkillers-prescriptions-united-states.html Rare Platlet Disorders: https://stepsforliving.hemophilia.org/basics-of-bleeding-disorders/types-of-bleeding-disorders/rare-platelet-disorders ISTH Congress 2017 Headlines: BioMarin and Spark: http://www.biopharmadive.com/news/hemophilia-ISTH-spark-alnylam-gene-therapy-biomarin/446849/    Idelvion: https://hemophilianewstoday.com/2017/07/14/hemophilia-b-pediatric-adult-patients-benefit-from-idelvion-studies-show/   Emicizumab: https://www.dddmag.com/article/2017/07/positive-results-emicizumab-phase-iii-studies-hemophilia-inhibitors   Nuwiq: http://www.businesswire.com/news/home/20170709005080/en/ISTH-2017-Berlin-Octapharma-presents-exciting-Nuwiq%C2%AE Q&A with R&D chief of Bioverativ: https://www.dddmag.com/article/2017/07/bioverativ-r-d-chief-breaks-down-data-blood-disorder-drug-pipeline   Steven Pipe presents small molecule therapies: http://isthcongressdaily.org/novel-therapies-hemophilia-small-molecules-treatment-hemophilia/   BloodFeed: https://www.bloodfeed.com Powering Through Podcast http://poweringthrough.org/podcast Ask The Expert Podcast http://bloodstreamexpert.com  

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, Allergan, Novartis, Uniqure, Horizon Pharma, Biogen, Recordati, Alexion Pharmaceuticals, AIFA, EMA, Diasorin, Kedrion Biopharma.Persone: David Nicholson (Allergan), Pierluigi Petrone (Global Virus Network), Massimo Galli (SIMIT), Sandra Horning (Roche), Riccardo Perfetti (Sanofi), Alessandro Segato (Aip), Carlo Agostini (Ospedale di Padova).Nuove terapie: emicizumab, insulina glargine.Patologie: Steatoepatite non alcolica, deficit familiare di lipoproteina lipasi, disordini del ciclo dell’urea, atrofia muscolare spinale, Malattia di Pompe, malattia granulomatosa cronica, osteopetrosi maligna severa, emoglobinuria parossistica notturna, Sindrome emolitico-uremica atipica, carcinoma uterino, emofilia A, diabete, immunodeficienze primitive.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, Allergan, Novartis, Uniqure, Horizon Pharma, Biogen, Recordati, Alexion Pharmaceuticals, AIFA, EMA, Diasorin, Kedrion Biopharma.Persone: David Nicholson (Allergan), Pierluigi Petrone (Global Virus Network), Massimo Galli (SIMIT), Sandra Horning (Roche), Riccardo Perfetti (Sanofi), Alessandro Segato (Aip), Carlo Agostini (Ospedale di Padova).Nuove terapie: emicizumab, insulina glargine.Patologie: Steatoepatite non alcolica, deficit familiare di lipoproteina lipasi, disordini del ciclo dell’urea, atrofia muscolare spinale, Malattia di Pompe, malattia granulomatosa cronica, osteopetrosi maligna severa, emoglobinuria parossistica notturna, Sindrome emolitico-uremica atipica, carcinoma uterino, emofilia A, diabete, immunodeficienze primitive.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/